SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 60 filers reported holding SUTRO BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $13,031,567 | +784.7% | 4,447,634 | +1606.1% | 0.03% | +750.0% |
| Q1 2024 | $1,472,932 | +20.2% | 260,696 | -8.8% | 0.00% | +33.3% |
| Q4 2023 | $1,225,636 | -33.8% | 285,696 | -46.4% | 0.00% | -40.0% |
| Q3 2023 | $1,850,027 | +90.4% | 533,149 | +155.1% | 0.01% | +66.7% |
| Q2 2023 | $971,869 | -84.8% | 209,004 | -73.6% | 0.00% | -86.4% |
| Q4 2022 | $6,388,048 | +61.9% | 790,600 | +11.2% | 0.02% | +37.5% |
| Q3 2022 | $3,946,000 | -44.3% | 711,000 | +89.6% | 0.02% | -48.4% |
| Q3 2021 | $7,084,000 | -66.5% | 375,000 | -67.0% | 0.03% | -67.4% |
| Q2 2021 | $21,129,000 | -3.1% | 1,136,600 | +18.6% | 0.10% | -6.9% |
| Q1 2021 | $21,809,000 | -28.7% | 958,200 | -32.0% | 0.10% | -31.5% |
| Q4 2020 | $30,596,000 | +201.3% | 1,409,314 | +39.5% | 0.15% | +186.5% |
| Q3 2020 | $10,155,000 | +118.1% | 1,010,495 | +68.4% | 0.05% | +73.3% |
| Q2 2020 | $4,656,000 | +26.9% | 600,000 | +86.1% | 0.03% | +57.9% |
| Q2 2019 | $3,669,000 | – | 322,377 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,824,542 | $41,527,000 | 15.56% |
| Samsara BioCapital, LLC | 1,675,579 | $38,136,000 | 7.03% |
| First Light Asset Management, LLC | 2,058,447 | $46,850,000 | 3.11% |
| FRAZIER MANAGEMENT LLC | 1,001,421 | $22,792,000 | 1.83% |
| AJU IB Investment Co., Ltd. | 175,000 | $3,983,000 | 1.50% |
| Altium Capital Management LP | 226,719 | $5,160,000 | 1.43% |
| Opaleye Management Inc. | 341,950 | $7,783,000 | 1.14% |
| Parkman Healthcare Partners LLC | 202,696 | $4,613,000 | 1.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 139,331 | $3,171,000 | 0.84% |
| Eventide Asset Management | 2,370,975 | $53,963,000 | 0.80% |